Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors.
CheckMate 649
Clinical trial
Gastric cancer
Immune checkpoint inhibitor
Nivolumab
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
06
03
2022
accepted:
23
05
2022
pubmed:
18
6
2022
medline:
24
8
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Although several randomized trials (RCTs) showed survival benefits of immune checkpoint inhibitor (ICI) plus first-line chemotherapy for advanced gastric or gastroesophageal cancer (AGC), these trials could enroll patients who fulfilled the strict eligibility criteria or waited for certain screening period for central assessment of PD-L1 status. We retrospectively compared characteristics and clinical outcomes of the patients with AGC who received first-line chemotherapy in control arm of RCTs with ICIs (control group) or clinical practice (practice group) at our institution from February 2016 to April 2019. The control group had a better baseline Eastern Cooperative Oncology Group performance status (PS0, 81.2% vs. 51.4%, p < 0.001) and a longer interval from first visit to first-line chemotherapy initiation (19 days vs. 9 days, p < 0.001) than the practice group. Median overall survival (OS) was 20.3 months in control group and 15.7 months in practice group, with a trend of longer OS in control group than that in practice group (hazard ratio, 0.71; p = 0.062). More patients in control group were treated with subsequent chemotherapy including ICIs. Patients with AGC in RCTs of ICIs had a better PS or a higher chance to receive subsequent chemotherapy, resulting in a better prognosis than those treated in clinical practice. This information should be considered when interpreting RCT results and applying new treatments into clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Although several randomized trials (RCTs) showed survival benefits of immune checkpoint inhibitor (ICI) plus first-line chemotherapy for advanced gastric or gastroesophageal cancer (AGC), these trials could enroll patients who fulfilled the strict eligibility criteria or waited for certain screening period for central assessment of PD-L1 status.
METHODS
METHODS
We retrospectively compared characteristics and clinical outcomes of the patients with AGC who received first-line chemotherapy in control arm of RCTs with ICIs (control group) or clinical practice (practice group) at our institution from February 2016 to April 2019.
RESULTS
RESULTS
The control group had a better baseline Eastern Cooperative Oncology Group performance status (PS0, 81.2% vs. 51.4%, p < 0.001) and a longer interval from first visit to first-line chemotherapy initiation (19 days vs. 9 days, p < 0.001) than the practice group. Median overall survival (OS) was 20.3 months in control group and 15.7 months in practice group, with a trend of longer OS in control group than that in practice group (hazard ratio, 0.71; p = 0.062). More patients in control group were treated with subsequent chemotherapy including ICIs.
CONCLUSION
CONCLUSIONS
Patients with AGC in RCTs of ICIs had a better PS or a higher chance to receive subsequent chemotherapy, resulting in a better prognosis than those treated in clinical practice. This information should be considered when interpreting RCT results and applying new treatments into clinical practice.
Identifiants
pubmed: 35713753
doi: 10.1007/s10147-022-02200-1
pii: 10.1007/s10147-022-02200-1
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1413-1420Informations de copyright
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Han JJ, Kim JW, Suh KJ et al (2019) Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. Asia Pac J Clin Oncol 15:158–165. https://doi.org/10.1111/ajco.13145
doi: 10.1111/ajco.13145
pubmed: 30848562
Unger JM, Barlow WE, Martin DP, et al (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Jnci J National Cancer Inst 106:dju002. https://doi.org/10.1093/jnci/dju002
Go RS, Frisby KA, Lee JA et al (2006) Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106:426–433. https://doi.org/10.1002/cncr.21597
doi: 10.1002/cncr.21597
pubmed: 16353206
Elting LS, Cooksley C, Bekele BN et al (2006) Generalizability of cancer clinical trial results. Cancer 106:2452–2458. https://doi.org/10.1002/cncr.21907
doi: 10.1002/cncr.21907
pubmed: 16639738
Ohno S, Mukai H, Narui K et al (2019) Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat 176:631–635. https://doi.org/10.1007/s10549-019-05276-y
doi: 10.1007/s10549-019-05276-y
pubmed: 31115845
Braunholtz DA, Edwards SJL, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect.” J Clin Epidemiol 54:217–224. https://doi.org/10.1016/s0895-4356(00)00305-x
doi: 10.1016/s0895-4356(00)00305-x
pubmed: 11223318
Peppercorn JM, Weeks JC, Cook EF et al (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363:263–270. https://doi.org/10.1016/s0140-6736(03)15383-4
doi: 10.1016/s0140-6736(03)15383-4
pubmed: 14751698
Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/s0140-6736(21)00797-2
doi: 10.1016/s0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Shitara K, Cutsem EV, Bang Y-J et al (2020) efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. Jama Oncol 6:1571–1580. https://doi.org/10.1001/jamaoncol.2020.3370
doi: 10.1001/jamaoncol.2020.3370
pubmed: 32880601
Kubota Y, Kawazoe A, Sasaki A et al (2020) The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin Cancer Res 26:3784–3790. https://doi.org/10.1158/1078-0432.ccr-20-0075
doi: 10.1158/1078-0432.ccr-20-0075
pubmed: 32156744
Fuchs CS, Muro K, Tomasek J et al (2017) prognostic factor analysis of overall survival in gastric cancer from two phase iii studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer 17:132–144. https://doi.org/10.5230/jgc.2017.17.e16
doi: 10.5230/jgc.2017.17.e16
pubmed: 28680718
pmcid: 5489542
Takahari D, Boku N, Mizusawa J et al (2014) Determination of prognostic factors in japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist 19:358–366. https://doi.org/10.1634/theoncologist.2013-0306
doi: 10.1634/theoncologist.2013-0306
pubmed: 24668328
pmcid: 3983816
Kang Y-K, Chen L-T, Ryu M-H et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234–247. https://doi.org/10.1016/s1470-2045(21)00692-6
doi: 10.1016/s1470-2045(21)00692-6
pubmed: 35030335
Kang Y-K, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471. https://doi.org/10.1016/s0140-6736(17)31827-5
doi: 10.1016/s0140-6736(17)31827-5
pubmed: 28993052
Catenacci DVT, Kang Y-K, Saeed A et al (2021) FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol. https://doi.org/10.1200/jco.2021.39.15_suppl.4010
doi: 10.1200/jco.2021.39.15_suppl.4010
Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859–1864. https://doi.org/10.1038/s41591-020-1063-5
doi: 10.1038/s41591-020-1063-5
pubmed: 33020649
Kather JN, Pearson AT, Halama N et al (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med 25:1054–1056. https://doi.org/10.1038/s41591-019-0462-y
doi: 10.1038/s41591-019-0462-y
pubmed: 31160815
pmcid: 7423299
Yamashita R, Long J, Longacre T, et al Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. The Lancet Oncology 22: 132–141.